Innoviva is a biotechnology business based in the US. Innoviva shares (INVA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $18.90 – a decrease of 6.34% over the previous week. Innoviva employs 112 staff and has a trailing 12-month revenue of around $352.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $18.90 |
|---|---|
| 52-week range | $13.41 - $21.28 |
| 50-day moving average | $19.65 |
| 200-day moving average | $17.11 |
| Wall St. target price | $19.00 |
| PE ratio | 24.987 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.77 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.24 from 2024-11-14
| 1 week (2024-11-08) | -4.66% |
|---|---|
| 1 month (2024-10-15) | -3.22% |
| 3 months (2024-08-15) | 4.51% |
| 6 months (2024-05-15) | 21.46% |
| 1 year (2023-11-15) | 38.72% |
|---|---|
| 2 years (2022-11-15) | 43.69% |
| 3 years (2021-11-15) | 11.28% |
| 5 years (2019-11-15) | 54.66% |
Valuing Innoviva stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innoviva's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Innoviva's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Innoviva shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Innoviva's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Innoviva's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Innoviva's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $221.2 million.
The EBITDA is a measure of a Innoviva's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $352.7 million |
|---|---|
| Operating margin TTM | 48.31% |
| Gross profit TTM | $276.1 million |
| Return on assets TTM | 9.37% |
| Return on equity TTM | 9.97% |
| Profit margin | 18.31% |
| Book value | $10.68 |
| Market Capitalization | $1.3 billion |
TTM: trailing 12 months
We're not expecting Innoviva to pay a dividend over the next 12 months.
Innoviva's shares were split on a 1241:1000 basis on 2 June 2014 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1241 shares. This wouldn't directly have changed the overall worth of your Innoviva shares – just the quantity. However, indirectly, the new 19.4% lower share price could have impacted the market appetite for Innoviva shares which in turn could have impacted Innoviva's share price.
Over the last 12 months, Innoviva's shares have ranged in value from as little as $13.41 up to $21.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innoviva's is 0.568. This would suggest that Innoviva's shares are less volatile than average (for this exchange).
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.